Next-generation pharmaceutical serialization foundation

A GxP-compliant, AI-enhanced traceability platform built for DSCSA and EU FMD

STRATEGIC OPPORTUNITIES

Strategic Investment & Acquisition
Architectural Asset Ready for Enterprise Scaling

The Egeli Lifesciences serialization foundation represents a rare opportunity for strategic acquisition or targeted investment. Engineered from the ground up to bypass the technical debt inherent in legacy L3/L4 systems, this platform offers a clean, modular IP asset ready for immediate market expansion.

Built on a containerized microservices architecture (Next.js frontend, NestJS backend, and high-availability PostgreSQL), the foundation is designed for frictionless multi-tenant SaaS deployment. For acquiring enterprise vendors or investment partners, this translates to drastically reduced time-to-market for a fully GxP-aligned, AI-enhanced traceability suite.

The architecture natively supports the rigorous data integrity demands of 21 CFR Part 11, EU Annex 11, and ALCOA+ principles, providing a de-risked, turnkey solution capable of absorbing impending DSCSA and EU FMD market demands.

Zero Legacy Debt: Modern, Dockerized deployment minimizes SDLC documentation overhead and accelerates feature rollout.
Enterprise Interoperability: Native APIs for seamless ingestion of L4 ERP Master Data and execution of complex EPCIS event choreographies.
Turnkey Compliance: Immutable audit trails and crypto-secure serial number provisioning built directly into the core logic.
Market-Ready AI Integration: Pre-built modules for automated root-cause analysis on serialization exceptions, significantly reducing QA labor overhead.